Cell Genesys, Inc., a biotechnology company, engages in development and commercialization of biological therapies for cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company's clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified to impart disease-fighting characteristics that are not found in conventional chemotherapeutic agents. Its GVAX cancer Immunotherapies include Prostate Cancer, a phase 3 product for the treatment of prostate cancer; Pancreatic Cancer, a phase 2 product for pancreatic cancer; and Leukemia, a phase 2 product for the treatment of acute myelogenous leukemia and chronic myelogenous leukemia. The company's Oncolytic Virus Therapy includes CG0070, a phase 1 product for the treatment of recurrent bladder cancer. It has a strategic alliance with Novartis AG to develop and commercialize oncolytic virus therapies, and has collaboration agreements with Medarex, Inc. and Amgen, Inc. The company was founded in 1988 and is headquartered in South San Francisco, California.

Abbott Molecular is an emerging leader in molecular diagnostics and the analysis of DNA, RNA, and proteins at the molecular level. They are committed to exploring new clinical frontiers through the development and delivery of system and assay solutions that are designed to provide earlier disease diagnosis, selection of appropriate therapies and monitoring of disease recurrence. Their expanding portfolio brings multiples technologies that enable fast, accurate results. Their state of the art research and manufacturing facilities have hundreds of scientists who are dedicated to producing quality and reliable products. Over 350 products are available in the areas of infectious disease, oncology, genetics, and automation. Some of these products include: the m2000 system which has an extensive assay menu in infectious disease featuring Abbott RealTime technology with a broad range of assays, PathVysion HER-2 DNA Probe Kit for breast cancer, ALK Break Apart FISH Probe Kit, and UroVysion Bladder Cancer Kit are important applications of the FISH technology.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Board of Regents of The University of Oklahoma is a private company headquartered in Norman, OK, with domestic subsidiaries, specializing in radio broadcasting stations.

CellAxia is a biotechnology startup that creates medications for cell treatment. Drug discovery bio-venture aiming at the practical application of advanced research such as cell therapy. It serves clients operating in the healthcare sector.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

Tengion, Inc. is an American development-stage regenerative medicine company founded in 2003 with financing from J&J Development Corporation, HealthCap and Oak Investment Partners, which is headquartered in Winston-Salem, North Carolina. Its goals are discovering, developing, manufacturing and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues, to address unmet medical needs in urologic, renal, gastrointestinal, and vascular diseases and disorders. The company creates these human neo-organs from a patient’s own cells or autologous cells, in conjunction with its Organ Regeneration Platform. The company declared Chapter 7 bankruptcy in December 2014, and it, along with its assets and tissue engineering samples, have been bought back by its creditors and former executives as of March 2015. The purchase was expedited, so that time-sensitive research can continue.

Cellsvision Guangzhou Medical Technology Service Co. Ltd. is a company headquartered in China. The firm provides artificial intelligence and medical big data analysis solutions to improve diagnostic efficiency & accuracy of pathologists.

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Sekisui Medical Co., Ltd., part of Sekisui Chemical Co., Ltd., is a company headquartered in Tokyo, Japan, that manufactures and markets in-vitro diagnostic substances and pharmaceutical products. Sekisui Chemical Co., Ltd. acquired Sekisui Medical Co., Ltd. from Daiichi Sankyo Co., Ltd. on October 02, 2006.

Beijing Shunlu Technology Co., Ltd., established on 2021-10-13, Business scope includes artificial intelligence system technology development,Technical Services,Technology development of high-end equipment intelligent manufacturing system,Technical Services;Technology development of power transmission and distribution, control and monitoring equipment,Technical Services,Technology development in the field of communication equipment systems,technology transfer,technical consulting,Technical Services;Optoelectronic Technology Development,Software Technology Development,Artificial intelligence vision technology development,Technology development in the field of control technology,Robot and system technology development;Sales Wujinjiaodian,communication equipment;software development;Technical consultation of artificial intelligence public service platform;Application software development;Computer System Integration Services;Basic Telecom Services.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Basic telecommunications business and projects subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Chr. Hansen A/S is a global bioscience company based in Hørsholm, Denmark that develops natural solutions for the food, beverage, nutritional, pharmaceutical and agricultural industries. The company is a supplier of food cultures, probiotics, enzymes and natural colors. Its products are used in cheese production, fermented milk, meat, food service, beverages, wine, fruit preparation, ice cream and desserts, confectionery, cereals, spreads, bakery products, snacks, dietary supplements, pharmaceuticals and agricultural products. Chr. Hansen A/S has development centers in Denmark, the United States, France and Germany including research facilities in Denmark and France. A large percentage of the employees engage in research and development for the international food and pharmaceuticals industries.

Tianjin Shengji Group Co., Ltd., established on 1998-10-21, Business scope includes technical services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Veterinary drug business;Disinfectant sales(Free of Hazardous Chemicals);Animal Husbandry and Fishery Feed Sales;Feed Additive Sales;fertilizer sales;Retailing of protective equipment for healthcare workers;Pet Food and Supplies Wholesale;Feed production special equipment sales;Refrigeration,Air Conditioning Equipment Sales;road freight transport(Does not contain dangerous goods)Non-residential real estate leases;property management;Machinery and Equipment Leasing;Car rental;Landscaping engineering construction;Import and export;Technology Import and Export;Grain Purchase;Purchase of primary agricultural products;Chinese herbal medicine acquisition.Limited to branch operations:Veterinary drug production;Disinfectant production(Free of Hazardous Chemicals);feed production;Feed additive production;Primary processing of non-edible agricultural products;fertilizer production;Manufacturing of bio-based materials.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Tianjin Yijia Agriculture and Animal Husbandry Technology Co., Ltd., established on 2014-06-18, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Feed Additive Sales;Animal Husbandry and Fishery Feed Sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:feed production;Feed additive production;Grain Purchase;Veterinary drug production;Veterinary drug business;road freight transport(Does not contain dangerous goods).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

Canji, Inc., part of Merck & Co., Inc., is a company headquartered in San Diego, CA, specializing in medical laboratories. Schering-Plough Corp., now part of Merck & Co., Inc. acquired Canji, Inc. on February 02, 1996 for $54.50 million.

Shenzhen Mingao Biotechnology Co., Ltd., established on 2021-04-21, Business scope includes general business items:engaged in biotechnology,Biotechnology,Basic Medicine,clinical medicine,Clinical Trial Research;Biological Technology,Basic Medicine,clinical medicine,Pharmacy,Clinical Trials,Gene Sequencing,tumor drug,Biomarker technology development,technical consulting,Technical Services,Technology transfer and technical training;Operating import and export business;Health Management Services;Data Processing and Storage Services;Data transaction service;market research;business services;marketing planning;account Serive.,The licensing program is:medical instruments(Ikind,IIkind,IIIkind),application,Electronic equipment,Research and development of agricultural, forestry, animal husbandry and fishery products and related consumables,Production,Sales and after-sales service;Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Polymer Materials,biomaterials,bioactive material,Biological product,Research and development of biotechnology products and reagent intermediates,Production,Sales and after-sales service.(The production site is set up separately)

Wuxi Zhongke Guangyuan Biomaterials Co., Ltd., established on 2008-07-24, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of bio-based materials;Import and export;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Production of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Engages in the research and development of biological technologies